Cover Image
市場調查報告書

豬菜過敏 : 開發平台分析

Ragweed Allergy - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 255966
出版日期 內容資訊 英文 37 Pages
訂單完成後即時交付
價格
Back to Top
豬菜過敏 : 開發平台分析 Ragweed Allergy - Pipeline Review, H2 2016
出版日期: 2016年07月13日 內容資訊: 英文 37 Pages
簡介

所謂豬菜過敏是指豬菜的花粉經由鼻子·喉嚨進入具有過敏體質的人體內,而引起過敏及氣喘的疾病。主要的症狀有噴嚏和鼻涕·鼻塞、喉嚨和耳朵內部發癢、蕁麻疹、眼睛腫·發癢等。主要治療藥有淤血消除藥和抗組織胺藥物,鼻子用皮質類固醇劑等。

本報告提供全球各國治療豬菜過敏用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查結果。

目錄

簡介

  • 分析範圍

豬菜過敏概要

治療藥的開發

  • 豬菜過敏開發中產品:概要
  • 豬菜過敏開發中產品:比較分析

各企業開發中的豬菜過敏治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品
  • 階段不明的產品

豬菜過敏治療藥:開發中的產品一覽(各企業)

豬菜過敏開發治療藥的企業

  • Anergis SA
  • Biomay AG
  • Circassia Pharmaceuticals Plc
  • Immunomic Therapeutics, Inc.
  • Stallergenes S.A.

豬菜過敏:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各投藥法
  • 各分子類型

藥物簡介

  • 豬菜花粉過敏原
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • AllerR
  • BM-34
  • Multi-LAMP-Vax
  • PL-101
  • 豬菜低過敏性疫苗
  • 氣喘,豬菜過敏,鼻子結膜炎疫苗

豬菜過敏治療藥:開發中產品的最新趨勢

豬菜過敏治療藥:暫停開發的產品

豬菜過敏治療藥:中止開發的產品

豬菜過敏相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8230IDB

Summary

Global Markets Direct's, 'Ragweed Allergy - Pipeline Review, H2 2016', provides an overview of the Ragweed Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ragweed Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ragweed Allergy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Ragweed Allergy
  • The report reviews pipeline therapeutics for Ragweed Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Ragweed Allergy therapeutics and enlists all their major and minor projects
  • The report assesses Ragweed Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Ragweed Allergy

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Ragweed Allergy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Ragweed Allergy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Ragweed Allergy Overview
  • Therapeutics Development
    • Pipeline Products for Ragweed Allergy - Overview
  • Ragweed Allergy - Therapeutics under Development by Companies
  • Ragweed Allergy - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Ragweed Allergy - Products under Development by Companies
  • Ragweed Allergy - Companies Involved in Therapeutics Development
    • Anergis SA
    • Biomay AG
    • Circassia Pharmaceuticals Plc
    • Immunomic Therapeutics, Inc.
  • Ragweed Allergy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AllerR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BM-34 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Multi-LAMP-Vax - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PL-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Asthma and Ragweed-Induced Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Ragweed Allergy - Dormant Projects
  • Ragweed Allergy - Discontinued Products
  • Ragweed Allergy - Product Development Milestones
    • Featured News & Press Releases
      • Dec 19, 2014: Anergis Granted U.S. Patent for Ragweed Allergy Vaccine AllerR
      • Dec 08, 2014: Circassia Announces Top-Line Results from Ragweed Allergy Treatment Phase IIb Chamber Study
      • Feb 21, 2013: Anergis To Present Preclinical Data On Ragweed Allergy Vaccine Candidate AllerR At AAAAI 2013 Annual Meeting
      • Jun 14, 2012: Anergis Reaches Several Preclinical Development Milestones With Ragweed Pollen Vaccine
      • Mar 07, 2012: Circassia's Ragweed Allergy Therapy Achieves Positive Phase II Clinical Results
      • Jan 19, 2012: Circassia Receives European Patent For Its Ragweed Allergy T-Cell Vaccine
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Ragweed Allergy, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Ragweed Allergy - Pipeline by Anergis SA, H2 2016
  • Ragweed Allergy - Pipeline by Biomay AG, H2 2016
  • Ragweed Allergy - Pipeline by Circassia Pharmaceuticals Plc, H2 2016
  • Ragweed Allergy - Pipeline by Immunomic Therapeutics, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Ragweed Allergy - Dormant Projects, H2 2016
  • Ragweed Allergy - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Ragweed Allergy, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top